+Vote!
Market Watch (Free subscription) | 04/09/2008
TEL AVIV (MarketWatch) -- Antisoma Plc, the London cancer-drug developer, said on Thursday that it started a Phase II study of AS1411, designed to treat metastatic kidney cancer. The trial will enroll around 30 patients who couldn't tolerate or who relapsed after previous treatments, including a tyrosine kinase inhibitor (sunitinib or sorafenib). The trial will evaluate the safety and efficacy of...
+Vote!
Red Orbit (Free subscription) | 04/09/2008
London, UK: 04 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).
+Vote!
EuroInvestor.co.uk (Free subscription) | 04/09/2008
London, UK: 04 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II study of AS1411 in metastatic renal cell carcin.. - Read more
+Vote!
Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 04/09/2008
LONDON, UK (MARKET WIRE)
+Vote!
Medical News Today (Free subscription) | 18/08/2008
Antisoma plc (LSE: ASM; USOTC: ATSMY) announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of docetaxel alone.
+Vote!
Red Orbit (Free subscription) | 15/08/2008
London, UK, and Cambridge, MA, 15 August 2008 - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of docetaxel alone.
+Vote!
The Earth Times Online Newspaper (Free subscription) | 15/08/2008
LONDON, UK -- 08/15/08 -- London, UK, and Cambridge, MA, 15 August 2008 - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients ..
+Vote!
Market Wire (Free subscription) | 06/08/2008
LONDON (MARKET WIRE) Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that its Chief Executive, Glyn Edwards, will be presenting at the Canaccord Adams Annual Global Growth Conference in Boston, MA.
+Vote!
Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 17/07/2008
LONDON (MARKET WIRE)
+Vote!
EuroInvestor.co.uk (Free subscription) | 09/07/2008
9 July 2008 London, UK: Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces the appointment of Mr Michael Lewis as a Non-Executive Director with immediate effect. Mr Lew.. - Read more
+Vote!
Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies (Free subscription) | 09/07/2008
LONDON (MARKET WIRE)
+Vote!
Red Orbit (Free subscription) | 07/07/2008
London, UK: 07 July 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces initial findings from its phase II trial of AS1411 in relapsed and refractory AML (acute myeloid leukaemia).
+Vote!
Red Orbit (Free subscription) | 16/06/2008
London, UK, and Copenhagen, Denmark: 16 June 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that a review of data supporting the development of AS1413 (amonafide L-malate; formerly Xanafide) in secondary acute myeloid leukaemia (AML) was presented yesterday at the European Hematology Association (EHA) meeting in Copenhagen, Denmark.
